Blood tyrosine determination for monitoring glucocorticoid therapy
DOI:
https://doi.org/10.30574/gscbps.2021.16.3.0266Keywords:
Glucocorticoid therapy, Glucocorticoid hormones, Tissue provision with glucocorticoids, Hepatic tyrosine aminotransferase, Tyrosine metabolism, Blood tyrosine versus glucocorticoidsAbstract
Glucocorticoid (GC) preparations are used in medicine for more than 70 years as the most powerful anti-inflammatory drugs also possessing immunosuppressive, anti-allergic, and antitoxic properties. However, administration of these unique preparations is associated with nearly inevitable severe adverse effects and a difficulty of their withdrawal. These adverse effects are caused not by toxicity of GC preparations, but are manifestations of their hormonal features. GC preparations are synthetic analogs of GC hormones which directly or indirectly participate in the regulation of virtually all reactions and processes in the body. Nevertheless, in clinical practice there is no index of tissue provision with GCs and real need in these hormones (or preparations). In this paper, blood tyrosine level was shown to characterize the tissue provision with GCs on two models: adrenalectomy in rats and the replacement GC therapy in congenital adrenal hyperplasia. Determination of blood tyrosine level made it possible to reveal the insufficiency of tissue provision with GGs in patients with bronchial asthma during the period of attacks. In patients with systemic lupus erythematosus, GC preparations were shown to be favorable on the background of increased blood tyrosine, i.e. on the insufficient tissue provision with GCs, and until the normalization of blood tyrosine, i.e. until the compensation of the hormonal insufficiency. On the background of normal blood tyrosine GC preparations in SLE were ineffective and side effects appeared rapidly. These observations allowed me to propose blood tyrosine level as a laboratory parameter for monitoring GC therapy.
The present paper consists of two parts: I) short reviews of the literature prerequisites for the proposal; II) the description of the author’s studies on blood tyrosine behavior in comparison with delivery and efficiency of glucocorticoid hormones or preparations in experiment (adrenalectomy in rats) and in some pathologies: congenital adrenal hyperplasia, bronchial asthma, and systemic lupus erythematosus.
Metrics
References
Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone, Compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. Preliminary report. Proc Staff Meet Mayo Clinic. 1949; 24 (1):181-197.
Hench PS, Kendall EC, Slocumb CH, Polley HF. Effect of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever, and certain other conditions; studies in clinical physiology. Arch Intern Med. 1950; 85(4):545-666.
Brunsting LA, Slocumb CH, Didcoct JW. Effect of cortisone on acute disseminated lupus erythematosus. Proc Staff Meet Mayo Clinic. 1950; 25:479-482.
Carryer HM, Koelsche GA, Prickman LE, et al. Effect of cortisone on bronchial asthma and hay fever occurring in subjects sensitive to ragweed pollen. Proc Staff Meet Mayo Clinic. 1950; 25:482-486.
Azarnoff DI. Symposium on steroid therapy. Introduction. Med Clinic North Amer. 1973; 57(5).
Liddle JW. Clinical pharmacology of the anti-inflammatory steroids. An up-to-date review of the cortisone series. Clin Pharmacol Therap. 1961; 2:615-635.
Vorlaender KO. Kortisontherapie by Auto-Immun-Krankheiten. Internist.1967; 8:94-102.
Albeaux-Fernet M, Gélinet M. La corticothérapie sans danger n’existe pas (Ėtude comparative des effets secondaire des différent corticoides). Sem Hôp Paris. 1960; 36:3401-3407.
Sigidin YA. Corticosteroid therapy in the modern medicine. On the 25th anniversary of the first use of cortisone (Russ). Sov Med. 1974; (7):78-82.
Fauci AS. 1979 Immunosuppressive and anti-inflammatory effect of glucocorticoids, in: Glucocorticoid Hormone Action. Berlin, 1979; 449-465.
Sapolsky R, Romero L, Munck A. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocrinol Rev. 2000; 21:55-89.
Rhen T, Cidlowsky JA. Anti-inflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med. 2005; 353:1711-23.
Kulinsky VI. Biochemical aspects of inflammation. Biochemistry (Moscow). 2007; 72(6):595-607.
Ramamoorphy S, Cidlowsky J. Corticosteroids: Mechanisms of action in health and disease. Rheum Clin North Am. 2018; 42:15-31.
Vandewalle J, Luypaert A, De Bussher K, Libert C. Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab. 2018; 29 (1):42-54.
Schäcke H, Schottelius A, Docke W, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA. 2004; 101:227-232.
Zimmermann C, Avery W, Finelli A, et al. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthr Res Ther. 2009; 11:12-26.
Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: An emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013; 154:993-1007.
Kavanagh RJ, Kam, PCA. Lazaroids: efficacy and mechanism of action of 21-aminosteroids in neuroprotection. Br J Anaesth. 2001; 86(1):110-119.
Carratu MR. Lazaroids and neuroprotection: What benefit? J Pharmacol Clin Res. 2017; 2(2): Editorial.
Ozbakir B, Crielaard BJ, Metselaar JM, et al. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. J Control Release. 2014; 190:624-636.
Perreti M, D-Acquisto F. Novel aspects of annexin 1 and Glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Review. Inflamm Allergy Drug Targets. 2006; 5(2):107-114.
Sundahl N, Bridelance J, Libert C, et al. Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. Pharmacol Therapeutics. 2015; 152:28-41.
Buttgereit F, Spies CM, Bijlsma JW. Novel glucocorticoids: where are we now and where do we want to go? Clin Exp Immunol. 2015; 33 (4 Suppl. 92):29-33.
Bordag N, Klie S, Jürchott K, et al. Glucocorticoid (dexamethasone)-induced metabolome changes in healthy males suggest prediction of response and side effects. Sci Rep. 2015; 5, Nov 3:15954.
Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti, RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: A review of glucocorticoid pharmacology and bone health. J Am Acad Dermatol. 2017; 76:1-9.
Yasir M, Goyal A, Bansal P, Santhalia S. Corticosteroid Adverse Effects, Last up-date: July 4. 2020, StatPearls (Internet).
Baxter J, Rousseau G. Glucocorticoid hormone action: An overview. In: Glucocorticoid Hormone Action, Baxter J, Rousseau G, Eds. Springer Verlag. 1979; 1-24.
Patel R, Williams-Dautovich J, Cummins C. Minireview: New molecular mediators of glucocorticoid receptor activity in metabolic tissues. Mol Endocrinol. 2014; 28:999-1011.
Ingle D. The role of adrenal cortex in homeostasis. J Endocrinol. 1952; 8:23-37.
Rose A, Herzig S. Metabolic control through glucocorticoid hormones: an update. J Mol Cell Endocrinol. 2013; 380:65-78.
Kuo T, McQueen A, Chen TC, Wang JC. Regulation of glucose homeostasis by glucocorticoids. Adv Exp Med Biol. 2015; 872:99-126.
Nicolaides NC, Charmandari E, Chrousos GP. Overview of glucocorticoids, in: Encyclopedia of Endocrine Diseases (Second Edition) 2018; 64-71.
Beisel W, Rappoport M. Interrelations between adrenocortical functions and infectious illnesses. New Engl J Med. 1969; 280:541-604.
Nicolaides N, Kuratzi E, Lamprokostopoulu A, et al. Stress, the stress system and the role of glucocorticoids. Neuroimmunomodulation. 2015; 22:6-19.
Dougherty TF, Brown HE, Berliner DL. Metabolism of hydrocortisone during inflammation. Endocrinology. 1958; 62:455-462.
Sutton JR, Casey JH. The adrenocortical response to competitive athletics in veteran athletes. J Clin Endocrinol Metab. 1975; 40:135-138.
Kass E, Finland M. Corticosteroids and infections. Adv Int Med. 1958; 9:45-80.
Haleem, M, Minton, S. Effects of adrenalectomy on Trypanosoma lewisi infection in white mice. J Tropic Med. 1966; 69:294-298.
Walzer PD, Powell RD, Joneda K. 1979 Experimental Pneumocystis carinii pneumonia in different strains of cortisonized mice. Infect Immunol. 1979; 24:939-947.
Tsukhno ZI, Slavnov VN, Panchenko NI, et al. Functional Investigation Methods in Endocrinology (Russ). Kiev. 1981.
Rozen VB. Fundamentals of Endocrinology (Russ). Moscow: 1980.
Knox W. 1955 Metabolism of phenylalanine and tyrosine. In: Symposium on Amino Acid Metabolism. Baltimora. 1955; 836-866.
Lin EC, Knox WE. Adaptation of the rat liver tyrosine-alpha-ketoglutarate transaminase. Biochim Biophys Acta. 1957; 26:85-88.
Kenney FT, Flora RM. Induction of tyrosine-alpha-ketoglutarate transaminase. J Biol Chem. 1957; 236:2699-2703.
Rosen F, Nichol C. Corticosteroids and enzyme activity, Vitamins Hormones. 1963; 21:135-214.
Baxter JD, Forsham PH. Tissue effects of glucocorticoids. Am J Med. 1972; 53:573-589.
Gelehrter T. Mechanisms of hormonal induction of enzymes. Metabolism. 1973; 22:85-100.
Protasova TN. Hormonal Regulation of Enzyme Activities (Russ). Moscow. 1975.
Feigelson M, Feigelson P. Relationships between hepatic enzyme induction, glutamate formation, and purinenucleotide biosynthesis in glucocorticoid action. J Biol Chem. 1966; 241:5819-5826.
Baxter J, Tomkins G. The relationship between glucocorticoid binding and tyrosine aminotransferase induction in hepatoma tissue cells. Proc Natl Acad Sci USA. 1970; 65:709-715.
Beato M, Kalimi M, Feigelson P. Correlation between glucocorticoid binding to specific cytosol receptors and enzyme induction in vivo, Biochem Biophys Res Commun. 1972; 47:1464-1472.
Gelehrter T, MacDonald R. Steroid specificity of the glucocorticoid inhibition of amino acid transport in rat hepatoma cells, Endocrinology. 1981; 109:476-482.
Thompson E. Glucocorticoid induction of tyrosine aminotransferase in cultured cells. In: Glucocorticoid Hormone Action. Springer Verlag. 1979; 203-213.
Hashimoto S, Schmidt W, Schütz G. Transcriptional activation of the rat liver tyrosine aminotransferase gene by cAMP. Proc Natl Acad Sci USA. 1984; 81(21):6637-6641.
Sun Y, DuBois D, Almon R, et al. Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokin Biopharmacol. 1998; 26:619-648.
Grange T, Cappabianca L, Flavin M, et al. In vivo analysis of the model tyrosine aminotransferase gene reveals multiple sequential steps in glucocorticoid receptor action. Oncogene. 2001; 20:3028-3038.
Sevaljeviċ L, Isenoviċ E, Vuloviċ M, et al. The responses of rat liver glucocorticoid receptors and genes for tyrosine aminotransferase alpha-2-macroglobulin and gamma-fibrinogen to adrenalectomy-, dexamethasone- and inflammation-induced changes in the levels of glucocorticoids and proinflammatory cytokines. Bio Signal Recept. 2001; 10(5):299-309.
Hazra A, Pyszeznsli N, DuBois D, et al. 2007 Modeling, receptor/gene-mediated effect of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by exogenous corticosteroids. J Pharmacokin Pharmacodynam. 2007; 34 (5):643-647.
Braunstein AE. Biochemistry of Amino Acid Metabolism (Russ). Moscow. 1969; 270- 293.
La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem. 1958; 230:251-260.
Armstrong M, Stave U. A study of plasma free amino acid levels. II. Normal values for children and adults. Metabolism. 1973a; 22:561-569.
Rivlin R, Melmon K. 1965 Cortisone-provoked depression of plasma tyrosine concentration: relation to enzyme induction in man. J Clin Invest. 1965; 44:1690-1698.
Kainova AS. Amino acid metabolism in patients with collagenoses (Russ), Vopr Revmatizma. 1974; no 1:68-73.
Armstrong M, Stave U. A study of plasma free amino acid levels. IV. Characteristic individual levels of the amino acids. Metabolism. 1973b; 22:821-825.
Betheil J, Feigelson M, Feigelson P. The differential effect of glucocorticoids on tissue and plasma amino acid levels. Biochem Biophys Acta. 1965; 104:92-97.
Pitot HC, Yatvin MB. Interrelationships of mammalian hormones and enzyme levels in vivo. Physiol Rev. 1973; 53:228-325.
Derks M, Dubois E, Koomans P, Boxtel C. Effect of hydrocortisone on plasma tyrosine concentration and lymphocyte counts in healthy volunteers. Clin Drug Invest. 1999; 18:391-401.
Nemeth S. The effect of stress or glucose feeding on hepatic tyrosine aminotransferase activity and liver and plasma tyrosine level of intact and adrenalectomized rats. Horm Metabol Res. 1978; 10:144-147.
Selye H. The Physiology and Pathology of Exposure to Stress. Montreal, 1950.
Levine R, Conn HO. Tyrosine metabolism in patients with liver disease. J Clin Invest. 1968; 46:2012-2020.
Nordlinger BM, Fulenwider JT, Ivey JI, et al. Tyrosine metabolism in cirrhosis, J Lab Clin Med. 1979; 94:832-840.
Clayton T, Lindon J, Everett, J, et al. Hepatotoxin-induced hypertyrosinemia and its toxicological significance. Arch Toxicol. 2007; 81:201-210.
Nishimura N, Yasui M, Okamoto H, et al. Intermediary metabolism of phenylalanine and tyrosine in diffuse collagen diseases. Arch Dermatol. 1958; 77:255-267.
Nishimura N, Maeda K, Yasui M, et al. Phenylalanine and tyrosine in collagen diseases. Arch Dermatol. 1961; 83:644-652.
Kainova AS, Kvyatkovskaya AN. Disorders in aromatic acid metabolism in rheumatism (Russ). Terap. Arch. 1965; no 11:44-52.
Demin AA, Zhuk RD. Amino acid composition and blood serum proteins in collagenoses and rheumatism (Russ). Trudy I MMI. 1966; 48:50-506.
Dovgallo, GK, Goncharik, II. 1973 Disorders in aromatic acid metabolism in patients with rheumatoid arthritis (Russ). Terap Arkh. 1973; no 11:86-91.
Rass IT, Borisov IA, Nikishova TA, Sura VV. Blood tyrosine dynamics and treatment with corticosteroids in systemic lupus erythematosus (Russ). Terap Arkh. 1977; 59(80):110-115.
Rass IT. Using corticosteroid hormones and tyrosine metabolism (Russ). Patol Fiziol. 1978; no. 2:87-91.
Udenfriend S, Cooper J. The chemical estimation of tyrosine and tyramine. J Biol Chem. 1952; 196(1):227-233.
Lascano-Gonzales JM. Les surrénales assesoires chez le Rat blanc. C R Soc Biol. 1932; 116:451-454.
Panov AN, Shalyapina VG. Dynamics of 11-hydroxycorticosteroid level in peripheral blood of rats after injection of different doses of hydrocortisone and corticosterone (Russ), Probl Endokrinol. 1968; no. 2:75-77.
Geller E, Yuwiler A, Schapiro S. Tyrosine aminotransferase activation or repression by a stress, Proc Soc Exper Biol. 1969; 130:458-461.
Buckingam JC, Hodges JR. Interrelationships of pituitary and plasma corticotrophin and plasma corticosterone in adrenalectomized and stressed, adrenalectomized rats. J Endocrinol. 1974; 63:213-222.
Fazekas JB. Uber die Mobilisierbarkeit des Korticosterongehalten des “Peripherishen Hormondepots”. Endokrinologie. 1964; 46: 133-138.
Ptak W. The effect of stress on the steroid hormone content in the brown adipose tissue of the rat. Folia Biol. 1962; 10:131-135.
Rass IT. Changes in blood tyrosine content in rats upon adrenalectomy and on substitutive injections of hydrocortisone (Russ) Dokl Akad Nauk SSSR. 1980; 250(6):1497-1499.
Rass IT, Kuznetsova ES, Zhukovsky MA. Blood tyrosine as an index of adequacy of the glucocorticoid replacement therapy in children with congenital adrenal hyperplasia (Russ) Pediatriya. 1979; 58(9):26-29.
Lukert BP. Editorial: glucocorticoid replacement – How much is enough? J Clin Endocrinol Metab. 2006; 91(3):793-794.
Bongiovanni AM, Eberlein MR. Defects of steroidal metabolism in subjects with adrenogenital syndrome. Metabolism. 1961; 10:917-935.
Zhukovsky MA, Buraya TI, Kuznetsova ES. Inborn Dysfunctions of Adrenal Cortex in Children (Russ). Moscow. 1977.
Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005; 365 (9477):2125-2136.
Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, J Clin Endocrinol Metab. 1999; 84(3):930-936.
Brook CCD. Congenital adrenal hyperplasia. In: The Human Adrenal Gland. London, 1979; 243-258.
Bonfig W, Dalla Pozza S, Schmidt H, et al. Hydrocortisone dosing during puberty in patients with congenital adrenal hyperplasia: An evidence-based recommendations, J Clin Endocrinol Metab. 2009; 94(10):3882-3888.
Whittle E, Falhammar H. Glucocorticoid regimen in the treatment of congenital adrenal hyperplasia: A systematic review and meta-analysis. J Endocrinol Soc. 2019; 3(6):1227-1245.
Ten S, New M, Maclaren N. Addison’s Disease 2001. J Clin Endocrinol Metab. 2001; 86(7):2909-2922.
Snell RS. Hormonal control of pigmentation in man and other animals, Adv Biol Skin. 1967; 8:447-466.
Christiansen JJ, Djurhuus CB, Gravholt CH, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: Studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab. 2007; 92(9):3553-3559.
Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respirat Med. 2005; 100:1307-1317.
Crofton J, Douglas A. Bronchial asthma, in: Respiratory Diseases. Oxford. 1975; 429-460.
Don H. Management of status asthmaticus, in: Bronchial Asthma: Principles of Diagnosis and Treatment. NY. 1981; 363-383.
Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Therap. 1993; 58(2):173-209.
Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med. 2014; 9(4):187-192.
Dunican EM, Fahy JV. Asthma and corticosteroids: time for a more precise approach to treatment. Eur Respirat J. 2017; 49: DOI: 10.1183/13993003.01167-2017.
Cayton RM, Howard P. Plasma cortisol and the use of hydrocortisone in the treatment of status asthmaticus. Thorax. 1973; 28:567-573.
Morrish DW, Sproule BJ, Aaron TH, et al. Hypothalamic-pituitary-adrenal function in extrinsic asthma. Chest. 1979; 75:161-166.
Karalus NC, Mahood CB, Dunn PJ, Speed JF. Adrenal function in acute severe asthma. NZ Med J. 1985; 98(788): 843-846.
Roberts S, Sutherland T, Slough J, et al. Adrenal insufficiency in asthma patients – Who is at risk? Eur Respirat J. 2016; 48: PA4899; DOI: 10. 1183/13993003.congress-2016.PA4899.
Chodosowska E. Exercise-induced bronchoconstriction in patients with bronchial asthma. Its prevention with anti-histaminic agent. Respiration. 1977; 34:31-35.
Vink NM, Boesen HM, Postma DS, et al. Basal or stress-induced cortisol and asthma development: the TRAILS study. Eur Respirat J. 2013; 41:846-852; DOI: 10.1183/09031936.00021212
Rass IT, Bunyatyan AF, Kornev BM, Turusina TA. Tyrosine, 11-oxycorticosteroids, and cortisol in blood of patients with bronchial asthma (Russ). Terap Arkh. 1978; 60(11):98-101.
Pavlikhina LV, Usvatova IY, Bunyatyan AF. Fluorometric method of separate determination of free and protein-bound proteins in blood plasma, in: Methods of Investigation of Some Systems of Hormonal Regulation (Russ). Moscow, 1967; 50-59.
Dubois EL. Lupus Erythematosus. McGraw Hill. 1966.
Dubois EL. Lupus Erythematosus. 2nd edition. Los Angeles. 1974.
Schroeder J, Euler H. Recognition and management of systemic lupus erythematosus. Drugs. 1977; 54:422-434.
Ioannou Y, Isenberg DA. Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge, Postgrad Med. 2002; 78:599-606.
Godblatt F, Isenberg DA. New therapies for systemic lupus erythematosus, Clin Exp Immunol. 2005; 40:205-212.
Nived O, Sturfelt G, Bengtsson AA. Improved lupus outcome. We are doing a good job, but could we do better? J Rheumatol. 2008; 59:176-180.
Ntali S, Tzanakakis M, Bertsias G, et al. What’s new in clinical trials in lupus? Int J Clin Rheumatol., 2009; 4(4):473-485.
Hashimoto H. Glucocorticoid therapy in systemic lupus erythematosus – Clinical analysis of 1,125 patients with SLE.In: TechOpen Published, 2012; 2012-11-28.
Durcan L, O’Dwyer T. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. June 2019; 393 (10188):2332-2343. DOI: 10. 1016/S0140-6736(19)30237-5.
Luijten R, Fritsch-Stork R, Bijlsma J, et al. The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Res. 2013; 12:617-628.
Stojan G, Petri M. The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years? Curr Treatm Opt Rheumatol. 2017; 3(3):164-172.
Apostolopoulos D, Morand EF. It hasn’t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017; 56 (Suppl_1):i114-i122.
Bazsó A, Szappanos A, Patós A, et al. The importance of glucocorticoid receptors in systemiMODUSc lupus erythematosus. A systematic review. Autoimmunity Revs. 2015; 14 (4):349-351.
Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. Febr 28 2008; 358:929-939.
Cohen PL. T- and B-cell abnormalities in systemic lupus. J Invest Dermatol. 1993; 100(1): 69-72.
Suárez-Fueyo A, Bradley SJ, Tsokos GC. T cells in systemic lupus erythematosus. Curr Opin Immunol. 2016; 43:32-38.
Tsai CY, Li KJ, Hsieh SC, et al. What’s wrong with neutrophils in lupus? Clin Exp Rheumatol. 2019; 37(4): 684-693.
P.S. Since the problem of glucocorticoid safety continued to exist, I wrote some papers (including the present manuscript) much later.
Rass IT. Blood content of tyrosine is an index of glucocorticoid action on metabolism. Biochemistry (Moscow). 2010; 75 (3): 353-366.
Rass IT. Tyrosine-based monitoring of glucocorticoid therapy of systemic lupus erythematosus. In: SYSTEMIC LUPUS ERYTHEMATOSUS. 2012; Almoalim H. ed: 163-184.
Irma Th. Rass. Can we tame glucocorticoids? Blood tyrosine as a new laboratory test. 2016: J Biomol Res Therap. 2016; 5:2: 1-6 (open access).
Irma Th. Rass. Adrenocortical response in influenza as a pattern for using corticosteroids in COVID-19. GSC Biol Pharm Sci. 2020; 12(03): 098-101.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
